A COMPARATIVE IN SILICO ANALYSIS OF GUT MICROBIOTA DYSBIOSIS IN OBESITY AND TYPE 2 DIABETES
Downloads
Objective: The proposed research is focused on examining the compositional and phylogenetic differences of the selected gut microbiota related to these conditions. Methods: Retrieval of sequence data was done in NCBI GenBank database and sequence alignment and phylogenetic tree methods were used to analyze the data. Also, heatmap analysis was used to represent changes in microbial abundance conditions. Results: The findings showed clear patterns of clustering and stable changes in microbes which indicated that a common dysbiotic profile existed in metabolic disorders. These results present the significance of gut microbiota as a biomarker and a target of therapeutic intervention. Novelty: Gut microbiota has been of great interest in that it is a determinant of metabolic disorders like obesity and type 2 diabetes.
P. J. Turnbaugh, R. E. Ley, M. A. Mahowald, V. Magrini, E. R. Mardis, and J. I. Gordon, “An obesity-associated gut microbiome with increased capacity for energy harvest,” Nature, vol. 444, no. 7122, pp. 1027–1031, 2009.
P. D. Cani, “Human gut microbiome: hopes, threats and promises,” Gut, vol. 67, no. 9, pp. 1716–1725, 2018.
H. Tilg, N. Zmora, T. E. Adolph, and E. Elinav, “The intestinal microbiota in metabolic disease,” Nat. Rev. Gastroenterol. & Hepatol., vol. 17, no. 5, pp. 279–299, 2020.
R. E. Ley, P. J. Turnbaugh, S. Klein, and J. I. Gordon, “Human gut microbes associated with obesity,” Nature, vol. 444, no. 7122, pp. 1022–1023, 2006.
L. Zhao, F. Zhang, and X. D. et al., “Gut bacteria selectively promoted by dietary fibers improve metabolic health,” Science (80-. )., vol. 359, no. 6380, pp. 1151–1156, 2019.
Y. Fan and O. Pedersen, “Gut microbiota in human metabolic health and disease,” Nat. Rev. Microbiol., vol. 19, no. 1, pp. 55–71, 2021.
D. P. Venegas, M. K. De la Fuente, G. Landskron, M. J. Gonzalez, R. Quera, and G. D. et al., “Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases,” Front. Immunol., vol. 10, p. 277, 2019.
A. O’Callaghan and D. van Sinderen, “Bifidobacteria and their role as members of the human gut microbiota,” Front. Microbiol., vol. 7, p. 925, 2016.
K. Makki, E. C. Deehan, J. Walter, and F. Backhed, “The impact of dietary fiber on gut microbiota in host health and disease,” Cell Host & Microbe, vol. 23, no. 6, pp. 705–715, 2018.
A. O’Callaghan and D. van Sinderen, “Bifidobacteria and their role as members of the human gut microbiota,” Front. Microbiol., vol. 10, p. 1421, 2019.
E. S. Chambers, A. Viardot, and A. P. et al., “Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults,” Gut, vol. 64, no. 11, pp. 1744–1754, 2015.
P. D. Cani, J. Amar, and M. A. I. et al., “Metabolic endotoxemia initiates obesity and insulin resistance,” Diabetes, vol. 56, no. 7, pp. 1761–1772, 2007.
J. Qin, Y. Li, and Z. C. et al., “A metagenome-wide association study of gut microbiota in type 2 diabetes,” Nature, vol. 490, pp. 55–60, 2012.
A. Kanazawa, M. Aida, and Y. Y. et al., “Effects of synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes mellitus: A randomized controlled study,” Nutrients, vol. 13, p. 558, 2021.
P. Louis and H. J. Flint, “Formation of propionate and butyrate by the human colonic microbiota,” Environ. Microbiol., vol. 19, no. 1, pp. 29–41, 2017.
Copyright (c) 2026 Mohammed Mudhafar Alkhuzaie, Mariam Walid Jabaar, Masara Methak Murad
This work is licensed under a Creative Commons Attribution 4.0 International License.
